In this study, we used various cell lines with EGFR TKI-resistance, including H1299, H1975, PC9/ER, and PC9/GR cells, to access whether ESB could be used for the treatment of NSCLC with EGFR TKI resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.